Physician profile
Daniel Jaffurs
NPI 1508895699
$1,513.03
in general payments reported to CMS, 2019-2025
13 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $9.20 · 2021: $241 · 2022: $338 · 2023: $234 · 2024: $239 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kls-Martin L.P. | $355.98 | 2020-2025 | |
| Mentor Worldwide LLC | $252.12 | 2021-2022 | |
| Abbvie INC. | $184.08 | 2023-2024 | |
| Tela Bio, INC. | $164.11 | 2021-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Davol INC. | $155.30 | 2022 | |
| Depuy Synthes Sales INC. | $107.54 | 2019 | |
| Polynovo North America LLC | $94.50 | 2025 | Novosorb Btm |
| Novartis Pharmaceuticals Corporation | $60.14 | 2024-2025 | |
| Integra Lifesciences Corporation | $55.82 | 2021-2022 | |
| Aroa Biosurgery Incorporated | $28.04 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $23.81 | 2023 | Hemangeol |
| Smith+Nephew, INC. | $20.37 | 2019 | |
| Cerapedics INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jaffurs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.